JosephDKhouryMD

PubMed

• 1265 citations
  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
  Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D Attygalle, Iguaracyra Barreto de Oliveira Araujo
  Leukemia. 2022-07-01
• 68 citations
  Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine.
  Carolyn C. Compton, James A. Robb, Matthew W. Anderson, Anna B. Berry, George G. Birdsong
  Archives of Pathology & Laboratory Medicine. 2019-07-22
• 39 citations
  Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.
  Sarah A. Bannon, Mark J. Routbort, Guillermo Montalban-Bravo, Rohtesh S. Mehta, Fatima Zahra Jelloul
  Frontiers in Oncology. 2021-01-28

Journal Articles

• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Focal Rosai–Dorfman Disease Coexisting with Lymphoma in the Same Anatomic Site: A Localized Histiocytic Proliferation Associated with MAPK/ERK Pathway Activation  
  Shaoying Li, L Jeffrey Medeiros, Joseph D Khoury, Nature
• Clinicopathologic and Molecular Features in Hairy Cell Leukemia-Variant: Single Institutional Experience  
  Tariq Muzzafar, L Jeffrey Medeiros, Xinyan Lu, Joseph D Khoury, Nature

Abstracts/Posters

• Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria
  Joseph Khoury, MD, Current Hematologic Malignancy Reports, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all